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Summary 1 
 2 
Background Hand–foot–and–mouth disease (HFMD) is a common childhood illness 3 
caused by enteroviruses. Increasingly it imposes a substantial disease burden 4 
throughout East and Southeast Asia. To better inform vaccine and other interventions, 5 
we characterized the epidemiology of HFMD in China based on enhanced 6 
surveillance.  7 
Methods We extracted epidemiological, clinical and laboratory data from reported 8 
HFMD cases during 2008–2012 and compiled climatic, geographic and demographic 9 
information. All analyses were stratified by age, disease severity, laboratory 10 
confirmation status and enterovirus subtype.  11 
Findings The surveillance registry captured 7,200,092 probable HFMD cases 12 
(annualized incidence, 1·2 per 1,000), of whom 3·7% were laboratory–confirmed and 13 
0·03% died. Incidence and mortality were highest in children aged 12–23 months (in 14 
2012: 38·2 cases per 1,000 and 1·5 death per 100,000). Median durations from onset 15 
to diagnosis and death were 1·5 days and 3·5 days respectively. The risk of 16 
cardiopulmonary or neurological complications was 1·1% and the severe-case fatality 17 
risk was 3·0%, with >90% of deaths associated with enterovirus 71. HFMD peaked 18 
annually in June in the North, whereas Southern China experienced semi-annual 19 
outbreaks in May and September/October. Geographic differences in seasonal 20 
patterns were weakly associated with climate and demographic factors (variance 21 
4 
 
explained 8-23% and 3–19%, respectively). 1 
Interpretation This is the largest population-based study to date of the epidemiology 2 
of HFMD. Future mitigation policies should take full account of the heterogeneities of 3 
disease burden identified. Additional epidemiologic and serologic studies are 4 
warranted to elucidate local HFMD dynamics and immunity patterns and optimize 5 
interventions.  6 
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 12 
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Introduction 1 
Hand-foot-and-mouth disease (HFMD) is a common infectious condition caused by a 2 
variety of enteroviruses, with enterovirus 71 (EV-A71) and Coxsackie virus A16 3 
(CA-V16) being the most commonly reported.1 Children under five years are 4 
particularly prone to HFMD, and most patients show self-limiting illness typically 5 
including fever, skin eruptions on hands and feet, and vesicles in the mouth. However, 6 
a small proportion has been known to rapidly develop neurological and systemic 7 
complications that can be fatal, particularly in cases associated with EV-A71.2 8 
EV-A71 was first identified in 1969 in California, USA3 and has become more 9 
predominant across the Asia–Pacific region in the past 15 years.4–̶11 10 
China established a national enhanced surveillance system for HFMD in May 2008 11 
partly in response to several large HFMD outbreaks during 2007 and early 2008.9 12 
Here we describe the enhanced HFMD surveillance system and characterize the 13 
epidemiology of the disease in China, focusing on age, seasonal, and geographic 14 
patterns from 2008 to 2012.  15 
 16 
Methods  17 
Enhanced national surveillance program  18 
Beginning on January 1, 2008, all probable and laboratory–confirmed HFMD cases 19 
were reported on a voluntary basis to the Chinese Centre for Disease Control and 20 
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Prevention (China CDC) in Beijing. On May 2, 2008, HFMD was made statutorily 1 
notifiable.  2 
 3 
Case definitions 4 
A probable HFMD case was defined as a patient with papular or vesicular rash on 5 
hands, feet, mouth, or buttocks, with or without fever. A confirmed case was defined 6 
as a probable case with laboratory evidence of enterovirus infection (including 7 
EV-A71, coxsackievirus A16 (CA-V16), or other non-EV-A71 and non-CA-V16 8 
enteroviruses) detected by reverse-transcriptase polymerase chain reaction (RT-PCR), 9 
real-time RT-PCR, or virus isolation.  10 
HFMD patients, whether probable or confirmed, were classified as severe if they 11 
experienced any neurological complications (aseptic meningitis, encephalitis, 12 
encephalomyelitis, acute flaccid paralysis, or autonomic nervous system dysregulation) 13 
and/or cardiopulmonary complications (pulmonary oedema, pulmonary haemorrhage, 14 
or cardiorespiratory failure); otherwise, they were categorized as mild cases.  15 
 16 
Collection and testing of specimens 17 
Given limited laboratory capacity during the first year of enhanced surveillance (from 18 
May 2008 through June 2009), clinical samples were collected from the first five mild, 19 
probable cases who visited hospital outpatient departments each week in each of 31 20 
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Chinese provinces (Appendix Figure 1). We also attempted to collect specimens from 1 
all severe cases. With enhanced capacity after June 2009, samples were collected from 2 
the first five mild, probable cases who visited hospital outpatient departments each 3 
month in each of the 3,074 counties or districts and from all severe cases (Appendix 4 
Figure 1).12 Depending on the symptoms and clinical status of each case, the 5 
appropriate clinical specimens, including throat swab, rectal swab, fecal sample, 6 
vesicular fluid, and/or cerebrospinal fluid, were collected. Sampling was systematic 7 
and did not follow community outbreaks.  8 
Specimens were placed in sterile viral transport medium and sent to provincial– or 9 
prefecture–level CDCs (n=425) for PCR or virus isolation, according to standardized 10 
protocols disseminated by the national CDC.13 Viral ribonucleic acid (RNA) was 11 
extracted using available commercial kits (most frequently, QIAamp Viral RNA Mini 12 
Kit, Qiagen, Valencia, CA, USA, and Geneaid Viral RNA Mini Kit, Geneaid Biotech, 13 
Taiwan China) as per the manufacturer’s protocols. RNA from each sample was tested 14 
for specific primers and probes that targeted pan-enterovirus, EV-A71, and CA-V16. 15 
Testing was carried out in biosafety level 2 facilities. Test results were classified into 16 
four categories: enterovirus negative, EV-A71 positive, CA-V16 positive, or positive 17 
for another enterovirus without further serotype identification.  18 
A small number of samples underwent virus isolation at provincial–level CDCs. 19 
According to national guidelines,12 at least ten enterovirus strains should be identified 20 
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in each province every month. Specimens were inoculated into human 1 
rhabdomyosarcoma (susceptible to EV-A71 and CA-V16) and Hep-2 (susceptible to 2 
other enteroviruses) cells. If cultures showed cytopathic effect (CPE), serotype 3 
identification was obtained by sequencing analysis14. A blind passage was done with 4 
all cultures showing no CPE after 7 days.  5 
 6 
Clinical and epidemiologic data  7 
Probable and confirmed case were reported on-line to the national CDC within 24 8 
hours of diagnosis, using a standardized form including basic demographic 9 
information (sex, date of birth, and address), case classification (probable or 10 
confirmed), severity (mild or severe), death status, date of symptoms onset, date of 11 
diagnosis, and date of death (if applicable), and virus type (EV-A71, CA-V16, other 12 
enterovirus) for confirmed cases.  13 
 14 
Climate, geographic, and demographic data  15 
To analyze the potential drivers of HFMD seasonality, we collected demographic, 16 
economic, geographic, and climatic information for all provinces from 2008 to 2012, 17 
including: 1) age–specific population denominators, population density, Gross 18 
Domestic Product, and Gross Regional Product;15 2) latitude and longitude of 19 
province capitals; 3) air, rail, road, and boat passenger data;16 4) meteorological data 20 
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including daily temperature, rainfall, relative humidity, air pressure, average vapor 1 
pressure, and hours of sunshine (Appendix Text 1 for details).17 Climate variables 2 
were aggregated by season (spring: April–June; autumn: September–November), to 3 
reflect the seasonal occurrence of HFMD peaks in surveillance data. The 31 provinces 4 
were further grouped into six climatic regions (Appendix Figure 2A).  5 
 6 
Data analysis  7 
Disease burden and severity of disease 8 
We included all cases with illness onset from January 1, 2008 through December 31, 9 
2012 in the analysis. We estimated age–specific rates of incidence, severe illness, and 10 
mortality by combining probable and confirmed cases. 95% confidence intervals (CIs) 11 
for rates were estimated with Poisson methods. For rates with denominator >100,000 12 
and numerator ≥20, we calculated 95% CIs assuming a normal distribution. We 13 
assessed the geographic distribution of cases across all 31 provinces, grouped into 14 
seven regions as shown in Appendix Figure 2B. We estimated the age specific 15 
case–severity risk (no. of severe cases/no. of probable and confirmed cases), 16 
case–fatality risk (no. of deaths/no. of probable and confirmed cases), and 17 
case–fatality risk of severe HFMD cases (no. of deaths/no. of severe cases), overall 18 
and stratified by serotype. In serotype-specific analyses, we estimated the number of 19 
serotype-specific HFMD cases by applying the distribution of serotypes among 20 
10 
 
specimens positive for enteroviruses and further serotyped to the universe of probable 1 
and confirmed cases.  2 
We calculated the distributions of times from illness onset to diagnosis, illness onset 3 
to death, and diagnosis to death by virus serotype. To identify predictors for severe or 4 
fatal outcomes, we applied logistic regression and backward selection of demographic 5 
and geographic variables, time from onset to diagnosis, and virus type (p-value for 6 
exclusion≥0·10), separately for laboratory–confirmed cases and probable cases. All 7 
analyses were carried out using SAS version 9.1 (SAS Institute, Cary, USA).  8 
Geographic patterns and seasonality 9 
To quantify HFMD seasonal patterns by province, we created heatmaps of the 10 
proportion of HMFD cases identified in each week of the year.18 We also fitted 11 
seasonal multiple linear regression models to weekly HFMD time series, including 12 
time trends and harmonic terms representing annual and semi-annual periodic cycles 13 
(Appendix Text 2).18,19 We extracted the amplitude and peak timing of the annual and 14 
semi-annual cycles based on model coefficients.18 The amplitude measures the 15 
difference between the maximum and minimum of a seasonal curve.19 16 
We used multivariate stepwise linear regression to study the association between 17 
HFMD seasonal characteristics and putative seasonal drivers, including geography, 18 
human mobility patterns, demographic, economic, and climate variables.18 19 
Epidemiologically relevant HFMD regions were identified by hierarchical clustering 20 
11 
 
using Ward’s minimum variance method, and predictors of these regions were 1 
identified through discriminant analysis.18 Time series were standardized for 2 
differences in sampling intensity over time and geography by dividing weekly case 3 
counts by the annual number of cases. 4 
 5 
Results  6 
Incidence description 7 
7,200,092 probable HFMD cases were reported to the China CDC surveillance system 8 
during 2008–2012, of which 3·7% were laboratory–confirmed and 0·03% died. The 9 
incidence of reported HFMD cases showed a sharp increase since the initiation of 10 
surveillance in 2008 (Table 1), due to improvements in reporting and surveillance. 11 
Reported disease rates reached a steady state at over 1·2 cases per 1,000 person–years 12 
during 2010-2012.  13 
HFMD incidence varied greatly with age, with highest rates in children aged six 14 
months to two years (Table 1). The median age of reported cases was 27 months 15 
(interquartile range = 18–43 months). Most cases occurred in children below the age 16 
of five, and incidence was very low in young infants aged <6 months, older children, 17 
and adults. The incidence of HFMD was 1·6 times higher in boys under 5 years than 18 
in girls of the same age (p<0·001).  19 
EV-A71 predominated among laboratory-confirmed cases, accounting for 45%, 80%, 20 
12 
 
and 93% of mild, severe, and fatal cases respectively (Figure 1). There was little 1 
variation in EV-A71 predominance by age (Figure 2A). EV-A71, CA-V16, and other 2 
enteroviruses co-circulated throughout the observation period in all regions 3 
(Appendix Figure 3). 4 
 5 
Clinical course 6 
The median time from illness onset to diagnosis, illness onset to death, and diagnosis 7 
to death were 1·5 days (interquartile range: 0·5–2·5 days), 3·5 days (interquartile 8 
range: 2·5–4·5 days), and 0·5 day (interquartile range: 0·5–1·5 days) respectively. 9 
The probability density distributions of the onset-to-diagnosis, onset-to-death, and 10 
diagnosis-to-death intervals were similar between probable and laboratory–confirmed 11 
cases of EV-A71 or other enteroviruses (Figure 3). However, CA-V-16 density 12 
distributions showed attenuated signal-to-noise ratio given the small number of deaths 13 
(n=25). 14 
 15 
Severity of disease 16 
Overall the case–fatality, case–severity, and severe case–fatality risks were 0·03% 17 
(range across years = 0·03–0·05%), 1·1% (range = 0·2–1·6%), and 3·0% (range = 18 
2·6–10·4%) respectively. Illness severity and death were inversely related to age 19 
(Table 2 and Figure 2B–2D). Consistently across all age groups, EV-A71 infections 20 
13 
 
were much more severe than CA-V16 infections (Figure 2B–2D). We performed 1 
sensitivity analyses on severity estimates by age and viral etiology limited to 2 
2010-2012 (Appendix Figure 4) and only 2012 (Appendix Figure 5), and found 3 
results were similar. Multivariate backward logistic regression of laboratory 4 
confirmed cases identified several mortality risk factors beyond young age and 5 
infection with EV-A71, including rural residence and long onset-to-diagnosis interval. 6 
Further, males and rural residents experienced higher risk of severe disease. Including 7 
probable cases in the analysis yielded similar risk predictors (Table 2).  8 
 9 
Seasonal characteristics 10 
National and province-specific patterns 11 
At the national scale, HFMD showed semi-annual peaks of activity, including a major 12 
peak in spring and early summer followed by a smaller peak in autumn, consistent 13 
between probable and confirmed time series (Figure 4).  14 
While Southern China experienced two outbreaks of HFMD peaking in May and 15 
October of each year, Northern China experienced a single annual peak in June 16 
(Figure 5-6). The annual amplitude of HFMD epidemics increased with increasing 17 
latitude and semi-annual periodicity was strongest in the South (Figure 5).  18 
Seasonal characteristics by serotype 19 
All enteroviruses exhibited latitudinal gradients in the amplitude of annual and 20 
14 
 
semi-annual epidemics (Appendix Figures 6–8). Annual peak timing of CA-V16 1 
activity occurred earlier than for other enteroviruses (p<0·001).  2 
Predictors of HFMD seasonality 3 
Putative predictors of HFMD seasonal characteristics were identified through 4 
multivariate stepwise regression (Appendix Table 1). We found that the annual 5 
amplitude of epidemics was associated with spring rainfall and spring sunshine in 6 
overall and serotype–stratified analyses (p<0·05, partial R2: 5%–23%; p<0·05, 7 
8%–23%, respectively). HFMD peak timing was associated with maximum spring air 8 
pressure in overall and serotype–stratified analyses (p<0·05, partial R2: 4%–12%). 9 
Predictors of semi-annual periodicity of HFMD epidemics were more varied. 10 
Population and transportation factors were moderately associated with HFMD 11 
seasonal characteristics, explaining 1–19% of the variance in epidemic timing and 12 
periodicity. Overall, multivariate models explained a moderate-to-high fraction of the 13 
variance in HFMD seasonal characteristics through multiple factors (40–92%). 14 
Epidemiological regions 15 
We identified two main geographic regions that share similar HFMD epidemiological 16 
characteristics: a northern region (latitude range 35·5°–46·2°N, plus Tibet, n=14) and 17 
a southern region (19·5°–34·8°N, n=17) (Figure 7). Serotype–specific analysis 18 
revealed a broadly similar split between Northern and Southern China, with a third 19 
epidemiological region including Western provinces identified for EV-A71 and 20 
15 
 
CA-V16 (Appendix Figures 9–11). Discriminant analysis confirmed that climate 1 
factors were the dominant predictors of HFMD epidemiological regions (Figure 7C, 2 
Appendix Figures 9–11). 3 
 4 
Discussion  5 
Our study relies on a large sample of more than 7·2 million HFMD cases reported to 6 
the national enhanced surveillance system during 2008–2012 in China and gives the 7 
first comprehensive account of the national burden and epidemiology of the disease 8 
(panel). The estimated HFMD incidence is 1·2 per 1,000 person–years in China and 9 
the disease is responsible for 350–900 reported deaths annually, predominantly among 10 
young children. As in other countries, we observed a predominance of EV-A71 11 
serotype among severe cases, with a particularly young median age at infection of 2·3 12 
years. Our large study covers 31 climatologically diverse provinces and suggests that 13 
while HFMD cases tend to occur in warmer months of the year throughout the country, 14 
peak timing and periodicity of epidemics varies with latitude. All serotypes causing 15 
HFMD appear to follow broadly similar geographic gradients, which are moderately 16 
associated with climate differences. 17 
The observed age profile of infection is in agreement with reports from other 18 
countries,4,20–22 and the particularly young mean age at infection suggests that 19 
enteroviruses causing HFMD are highly transmissible. Relative sparing of infants 20 
16 
 
younger than six months was most likely due to protection by maternal antibodies.23,24 1 
Infection with the causative viruses appears to confer lifelong immunity at least to 2 
disease and possibly infection given the virtual absence of adult cases.  3 
Our large-scale analysis of HFMD seasonal patterns identified two main 4 
epidemiological regions corresponding to Northern China, where HFMD peaks in 5 
summer, and Southern China, which experiences two HFMD peaks in spring and 6 
autumn. A highly transmissible, strongly immunizing disease requires constant 7 
replenishment of susceptibles to sustain semi-annual, even annual, epidemics. 8 
Experience from Asia–Pacific countries has shown biennial25 or triennial20,21 9 
outbreaks against a background total fertility rate of 1·3–3 births per woman,26 10 
compared to China’s 1·6 births per woman under the longstanding one–child policy.27 11 
In contrast, annual epidemics were reported in Japan and Malaysia,6,25 consistent with 12 
observed patterns in Northern China, while semi-annual epidemics were reported in 13 
Hong Kong SAR, South Taiwan of China, and Vietnam,8,10,21, in line with our 14 
Southern China data. Further, our data indicate that EV-A71 epidemics occur annually 15 
in China, in contrast to Japan and Malaysia where this serotype circulates every three 16 
or four years.6,25 HFMD periodicity may be complicated by interference between the 17 
causative enterovirus serotypes, perhaps associated with cross–serotype immunity. 18 
Overall, the drivers of HFMD periodicity are not fully understood and worthy of 19 
further study.   20 
17 
 
Although HFMD seasonal patterns were associated with precipitations, sunshine, 1 
temperature, and air pressure, no single climatic variable explained the complexity of 2 
HFMD seasonality across China. Our results confirm those of previous time series 3 
analyses suggesting a relationship between HFMD and climatic factors in Singapore, 4 
Hong-Kong, Southern China, and Japan.29–32 Moreover, the occurrence of 5 
poliomyelitis, a disease caused by another enterovirus, may be associated with 6 
humidity.33 Humidity was a weak predictor of HFMD seasonal patterns in our large 7 
Chinese study, which encompasses a greater diversity of climate zones and 8 
populations than previously studied. The HFMD epidemiological patterns in Hainan 9 
and Tibet were apparently different from those in the other provinces (Fig. 4). This 10 
divergence could be due to the extreme, unique climate of these two outliers: Hainan 11 
is the only tropical region of China; while the climate in Tibet is very particular and 12 
complex because of the great altitude. We cannot rule out artefactual surveillance 13 
biases, in part due to the lack of financial and human resources (in Tibet in particular). 14 
Clearly, more work is needed to clarify the local drivers of HFMD seasonality in 15 
South East Asia.  16 
Systematic, population–representative seroepidemiology studies across the age 17 
spectrum from mother–infant pairs through the first ten years of life would greatly 18 
refine our understanding of HFMD dynamics in different regions. Previous 19 
cross–sectional serosurveys have provided age-specific estimates of the cumulative 20 
18 
 
incidence of infection at certain ages.34–37 Prospective longitudinal serological studies 1 
could provide more detailed information on age–specific incidence of infection and 2 
disease, risk factors for infection, and the protection against new infections conferred 3 
by previous infections with the same or different viruses. Longitudinal serosurveys 4 
were instrumental to elucidate the acquisition of infection and immunity in other 5 
complex disease systems involving competition between viruses, which in turn 6 
informed vaccination strategies.38  7 
EV-A71 infection in early infancy conferred the gravest risks for clinical severity and 8 
fatality.21,39 Several candidate vaccines against EV-A71 are currently undergoing 9 
regulatory vetting in China.40 Whether and how these should be deployed require 10 
further assessment of cost–effectiveness, feasibility and contextual considerations in 11 
different regions. Transmission models are needed to fully assess the direct and 12 
indirect benefits of vaccination, and the risk of serotype replacement given use of a 13 
monovalent vaccine.  14 
Our severity data highlight two independent risk factors: 1) each extra day since 15 
symptom onset was associated with a 1% higher risk of mortality, and 2) those living 16 
in a rural area had a one–quarter excess risk of death from infection. In addition to 17 
rural–urban disparity in health care access and advanced life-sustaining technology,41 18 
widespread and inappropriate use of glucocorticoids and pyrazolones in mild HFMD 19 
stages42,43 could have precipitated critical illness and death. 20 
19 
 
Several limitations bear mention. First, as for any common, self-limiting illness, 1 
surveillance only captures the tip of the clinical iceberg while most cases go 2 
undetected because their condition is asymptomatic, or the patient does not seek 3 
formal care, or he/she is not diagnosed and reported. Second, access to and provision 4 
of health care as well as technical capacity varied between and sometimes within 5 
provinces and there was no formal quality assurance or systematic audit for HFMD 6 
surveillance. In particular, we cannot rule out that surveillance bias explained the 7 
marked differences in HFMD patterns observed in Hainan and Tibet, relative to other 8 
provinces (Fig. 4). Third, data collected during the first year of rollout are likely less 9 
reliable than in more recent years. Fourth, we did not have data on mixed enterovirus 10 
infections44 and were unable to serotype enteroviruses beyond CV-A16 and EV-A71. 11 
In particular, we were unable to monitor serotype CV-A6, which has become more 12 
predominant in Southern China.45 Fifth, some of severe neurological illnesses caused 13 
by EV-A71 may have been missed by using a strict HFMD case definition. Sixth, our 14 
study was based on a descriptive analysis of surveillance data. We unfortunately 15 
cannot yet determine/estimate a threshold for yearly epidemic –this is beyond the 16 
scope of our study. 17 
 18 
In conclusion, we found substantial HFMD illness and mortality associated with 19 
co-circulating EV-A71, CA-V16, and other enterovirus in China, disproportionately 20 
20 
 
affecting young children aged <5 years. Younger age, infection with EV-A71, and 1 
living in rural area are risk factors for severe disease. Our study also uncovered 2 
intriguing differences in HFMD seasonality across China, which may be associated 3 
with climate. Overall, our study provides robust, population-based, national data to 4 
prioritize EV-A71 vaccination and optimize the timing of routine vaccination 5 
regionally. Further, our results will serve as a pre-vaccination baseline against which 6 
future interventions can be compared. More broadly, further studies are warranted to 7 
elucidate the dynamics and immunity patterns of HFMD, a rising public health 8 
problem in Asia.  9 
10 
21 
 
References  1 
1. Melnick JK. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and 2 
newer enteroviruses. In: Fields BN, Knipe DM, Howley PM, Chanlock RM, 3 
Melnick JL, Monath TP, et al., editors. Field's virology. 3rd ed. Philadelphia: 4 
Lippincott-Raven; 1996. p. 655-712. 5 
2. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, 6 
diagnosis, and management of enterovirus 71. Lancet Neurol. 2010; 9: 7 
1097-105. 8 
3. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from 9 
patients with disease of the central nervous system. J Infect Dis. 1974; 129: 10 
304-9. 11 
4. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, et al. Deaths 12 
of children during an outbreak of hand, foot, and mouth disease in sarawak, 13 
malaysia: clinical and pathological characteristics of the disease. For the 14 
Outbreak Study Group. Clin Infect Dis. 2000; 31: 678-83. 15 
5. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of 16 
enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working 17 
Group. N Engl J Med. 1999; 341: 929-35. 18 
6. Hand, foot and mouth disease in Japan, 2002-2011. IASR. 33(3). Available at: 19 
http://idsc.nih.go.jp/iasr/33/385/tpc385.html. 20 
22 
 
7. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot 1 
and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect 2 
Dis. 2003; 9: 78-85. 3 
8. Tu PV, Thao NT, Perera D, Huu TK, Tien NT, Thuong TC, et al. Epidemiologic 4 
and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 5 
2005. Emerg Infect Dis. 2007; 13: 1733-41. 6 
9. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging 7 
recombinant human enterovirus 71 responsible for the 2008 outbreak of hand 8 
foot and mouth disease in Fuyang city of China. Virol J. 2010; 7: 94. 9 
10. Ma E, Chan KC, Cheng P, Wong C, Chuang SK. The enterovirus 71 epidemic in 10 
2008--public health implications for Hong Kong. Int J Infect Dis. 2010; 14: 11 
e775-80. 12 
11. Seiff A. Cambodia unravels cause of mystery illness. Lancet. 2012; 380: 206. 13 
12. China Ministry of Health. Guideline for HFMD public health response. 2009. 14 
Available at: 15 
http://www.chinacdc.cn/jkzt/crb/szkb/jszl_2275/200906/t20090612_24707.html. 16 
Accessed September 23 2013. 17 
13. Protocol of sample collection and laboratory tests for HFMD cases. 2009. 18 
Available at: 19 
http://www.chinacdc.cn/jkzt/crb/szkb/jszl_2275/200906/W0201301065228554620 
23 
 
5929.pdf. Accessed October 25 2013. 1 
14. Zhang Y, Wang J, Guo W, Wang H, Zhu S, Wang D, et al. Emergence and 2 
transmission pathways of rapidly evolving evolutionary branch C4a strains of 3 
human enterovirus 71 in the Central Plain of China. PLoS One. 2011; 6: e27895. 4 
15. National Bureau of Statistics of China. National census in China in 2010. 5 
Available at: http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.html. Accessed 6 
23 September 2012.  7 
16. Yearbook of China integrated transport. Available at: 8 
http://www.zgjtnj.com/about/?2.html. Accessed June 15 2012. 9 
17. Climatic Data Center, National Meteorological Information Center, CMA. 10 
Available at: http://data.cma.gov.cn/index.jsp. Accessed April 04 2013. 11 
18. Yu H, Alonso WJ, Feng L, Tan Y, Shu Y, Yang W, Viboud C. Characterization of 12 
regional influenza seasonality patterns in China and implications for vaccination 13 
strategies: spatio-temporal modelling of surveillance data. PLoS Med. 2013: 14 
Nov 19. In Press. 15 
19. Naumova EN, Jagai JS, Matyas B, DeMaria A, Jr., MacNeill IB, Griffiths JK. 16 
Seasonality in six enterically transmitted diseases and ambient temperature. 17 
Epidemiol Infect. 2007; 135: 281-92. 18 
20. Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT. Epidemiology and 19 
control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad 20 
24 
 
Med Singapore. 2009; 38: 106-12. 1 
21. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year study of 2 
epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med 3 
Hyg. 2007; 77: 188-91. 4 
22. Momoki ST. Surveillance of enterovirus infections in Yokohama city from 2004 5 
to 2008. Jpn J Infect Dis. 2009; 62: 471-3. 6 
23. Wang SM, Ho TS, Lin HC, Lei HY, Wang JR, Liu CC. Reemerging of 7 
enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin 8 
Microbiol Infect Dis. 2012; 31: 1219-24. 9 
24. Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, et al. Retrospective 10 
study of the incidence of HFMD and seroepidemiology of antibodies against 11 
EV71 and CoxA16 in prenatal women and their infants. PLoS One. 2012; 7: 12 
e37206. 13 
25. Podin Y, Gias EL, Ong F, Leong YW, Yee SF, Yusof MA, et al. Sentinel 14 
surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the 15 
first 7 years. BMC Public Health. 2006; 6: 180. 16 
 26. The World Bank. Fertility rate, total (births per woman). Available at: 17 
http://data.worldbank.org/indicator/SP.DYN.TFRT.IN?page=2. Accessed 18 
February 20 2013. 19 
27. Hesketh T, Lu L, Xing ZW. The effect of China's one-child family policy after 20 
25 
 
25 years. N Engl J Med. 2005; 353: 1171-6. 1 
28. Ma E, Lam T, Chan KC, Wong C, Chuang SK. Changing epidemiology of hand, 2 
foot, and mouth disease in Hong Kong, 2001-2009. Jpn J Infect Dis. 2010; 63: 3 
422-6.  4 
29. Hii YL, Rocklov J, Ng N. Short term effects of weather on hand, foot and mouth 5 
disease. PLoS One. 2011; 6: e16796. 6 
30. Ma E, Lam T, Wong C, Chuang SK. Is hand, foot and mouth disease associated 7 
with meteorological parameters? Epidemiol Infect. 2010; 138: 1779-88. 8 
31. Onozuka D, Hashizume M. The influence of temperature and humidity on the 9 
incidence of hand, foot, and mouth disease in Japan. Sci Total Environ. 2011; 10 
410-411: 119-25.  11 
32. Huang Y, Deng T, Yu S, Gu J, Huang C, Xiao G, et al. Effect of meteorological 12 
variables on the incidence of hand, foot, and mouth disease in children: a 13 
time-series analysis in Guangzhou, China. BMC Infect Dis. 2013; 13: 134. 14 
33. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of 15 
poliomyelitis deconstructed. Am J Epidemiol. 2010; 172(11): 1213-29. 16 
34. Zhu Z, Zhu S, Guo X, Wang J, Wang D, Yan D, et al. Retrospective 17 
seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 18 
circulated wildly in central and southern China before large-scale outbreaks 19 
from 2008. Virol J. 2010 Nov 4;7:300. 20 
26 
 
35. Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, et al. Retrospective 1 
study of the incidence of HFMD and seroepidemiology of antibodies against 2 
EV71 and CoxA16 in prenatal women and their infants. PLoS One. 3 
2012;7(5):e37206. 4 
36. Zeng M, El Khatib NF, Tu S, Ren P, Xu S, Zhu Q, et al. Seroepidemiology of 5 
Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin 6 
Virol. 2012 Apr;53(4):285-9. 7 
37. Yu H, Wang M, Chang H, Lu J, Lu B, Li J, et al. Prevalence of antibodies 8 
against enterovirus 71 in children from Lu'an City in Central China. Jpn J Infect 9 
Dis. 2011;64(6):528-32. 10 
38. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell 11 
S, et al. Rotavirus infections in infants as protection against subsequent 12 
infections. N Engl J Med. 1996; 335: 1022-8. 13 
39. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of 14 
enterovirus 71 infection and associated hand, foot, and mouth 15 
disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002; 16 
109: e88. 17 
40. Liang Z, Mao Q, Gao F, Wang J. Progress on the research and development of 18 
human enterovirus 71 (EV71) vaccines. Front Med. 2013; 7: 111-21. 19 
41. Shi L. Health care in China: a rural-urban comparison after the socioeconomic 20 
27 
 
reforms. Bull World Health Organ. 1993; 71: 723-36. 1 
42. Jiang Q, Yu BN, Ying G, Liao J, Gan H, Blanchard J, et al. Outpatient 2 
prescription practices in rural township health centers in Sichuan Province, 3 
China. BMC Health Serv Res. 2012; 12: 324. 4 
43. Ma H, He F, Wan J, Jin D, Zhu L, Liu X, et al. Glucocorticoid and pyrazolone 5 
treatment of acute fever is a risk factor for critical and life-threatening human 6 
enterovirus 71 infection during an outbreak in China, 2008. Pediatr Infect Dis J. 7 
2010; 29: 524-9. 8 
44. Yan XF, Gao S, Xia JF, Ye R, Yu H, Long JE. Epidemic characteristics of hand, 9 
foot, and mouth disease in Shanghai from 2009 to 2010: Enterovirus 71 10 
subgenotype C4 as the primary causative agent and a high incidence of mixed 11 
infections with coxsackievirus A16. Scand J Infect Dis. 2012; 44(4): 297-305. 12 
45. He YQ, Chen L, Xu WB, Yang H, Wang HZ, Zong WP, et al. Emergence, 13 
circulation, and spatiotemporal phylogenetic analysis of coxsackievirus a6- and 14 
coxsackievirus a10-associated hand, foot, and mouth disease infections from 15 
2008 to 2012 in Shenzhen, China. J Clin Microbiol. 2013; 51(11): 3560-6. 16 
28 
 
Table 1. Estimated rates of incidence, severe illness and mortality amongst all HFMD cases by age group 
Age 
group 
Incidence rates (95% confidence interval), 
 per 1,000,000 
   Severe illness rates (95% confidence 
interval), per 1,000,000 
  Mortality rates (95% confidence 
interval), per 1,000,000 
2008 2009 2010 2011 2012  2008 2009 2010 2011 2012  2008 2009 2010 2011 2012 
Total 369.2 
(368.2- 
370.3)  
869.3 
(867.8- 
870.9) 
1352.9 
(1350.9- 
1354.9) 
1221.3 
(1219.5- 
1223.2) 
1616.4 
(1614.3- 
1618.6) 
 0.9 
(0.9- 
1.0) 
10.4 
(10.2- 
10.6) 
21.3 
(21.0- 
21.5) 
14.1 
(13.9- 
14.3) 
15.6 
(15.4- 
15.8) 
 0.1  
(0.1- 
0.1) 
0.3 
(0.2- 
0.3) 
0.7 
(0.6- 
0.7) 
0.4  
(0.4- 
0.4) 
0.4 
(0.4- 
0.5) 
<6 
months 
673.7 
(655.5- 
691.8) 
1319.9 
(1294.9- 
1345.0) 
2259.6 
(2227.1- 
2292.1) 
2372.5 
(2338.0- 
2407.1) 
4014.7 
(3966.9- 
4062.5) 
 3.8 
(2.6- 
5.5) 
35.9 
(31.7- 
40.0) 
60.5 
(55.1- 
65.8) 
45.5 
(40.7- 
50.2) 
65.0 
(58.9- 
71.1) 
 0.6  
(0.2- 
1.5) 
2.0 
(1.2- 
3.2) 
3.3 
(2.2- 
4.8) 
2.4 
(1.4- 
3.7) 
1.5 
(0.7- 
2.7) 
6-11 
months 
7186.5 
(7132.1- 
7241.0) 
18561.8 
(18475.6- 
18647.9) 
28042.1 
(27937.1- 
28147.1) 
25539.2 
(25435.2- 
25643.2) 
28862.1 
(28744.5- 
28979.7) 
 27.3 
(23.9 
-30.6) 
317.1 
(305.9-
328.4) 
589.6 
(574.4-
604.8) 
336.9 
(325.0- 
348.9) 
407.4 
(393.4- 
421.4) 
 3.8  
(2.6- 
5.2) 
10.5 
(8.5- 
12.6) 
27.1 
(23.9- 
30.4) 
11.5 
 (9.3- 
13.7) 
13.3 
(10.8- 
15.9) 
12-23 
months 
8180.8 
(8137.1- 
8224.4) 
19148.5 
(19082.5- 
19214.4) 
29480.4 
(29399.1- 
29561.6) 
30215.9 
(30130.6- 
30301.2) 
38191.1 
(38096.4- 
38285.8) 
 26.4 
(23.9- 
28.9) 
326.8 
(318.2-
335.4) 
626.1 
(614.3-
637.9) 
457.3 
(446.8- 
467.8) 
492.4 
(481.6- 
503.1) 
 3.2 
(2.3- 
4.1) 
8.6 
(7.2- 
10.0) 
20.2 
(18.1- 
22.4) 
12.9 
(11.2- 
14.7) 
15.3 
(13.4- 
17.2) 
24-59 
months 
4760.6 
(4741.1- 
4780.1) 
11306.9 
(11276.9- 
11336.8) 
16848.0 
(16811.4- 
16884.5) 
16815.9 
(16777.9- 
16853.8) 
23111.3 
(23067.3- 
23155.3) 
 8.8 
(8.0- 
9.6) 
93.2 
(90.5- 
95.9) 
204.8 
(200.8-
208.8) 
163.3 
(159.5- 
167.0) 
182.1 
(178.2- 
186.0) 
 0.6 
(0.4- 
0.9) 
1.8 
(1.4- 
2.2) 
5.2 
(4.6- 
5.9) 
3.9 
 (3.3- 
4.5) 
4.1 
(3.5- 
4.6) 
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Table 1. (continued) 
Age 
group 
Incidence rates (95% confidence interval), 
 per 1,000,000 
   Severe illness rates (95% confidence 
interval), per 1,000,000 
  Mortality rates (95% confidence 
interval), per 1,000,000 
2008 2009 2010 2011 2012  2008 2009 2010 2011 2012  2008 2009 2010 2011 2012 
5-9 
years 
580.7 
(575.3- 
586.2) 
1045.1 
(1037.8- 
1052.4) 
1712.0 
(1702.8- 
1721.2) 
1565.3 
(1556.2- 
1574.4) 
2706.5 
(2694.5- 
2718.5) 
 0.7 
(0.5- 
0.9) 
5.2 
(4.7- 
5.7) 
10.4 
(9.7- 
11.1) 
8.8  
(8.1- 
9.5) 
10.2 
(9.5- 
10.9) 
 0.0 
(0.0- 
0.1) 
0.1 
(0.0- 
0.1) 
0.1 
(0.1- 
0.3) 
0.1  
(0.0- 
0.2) 
0.1 
(0.1- 
0.2) 
10-14 
years 
68.4 
(66.7- 
70.1) 
132.3 
(129.9- 
134.7) 
216.3 
(213.0- 
219.5) 
186.7 
(183.5- 
189.9) 
277.2 
(273.4- 
281.0) 
 0.1 
(0.0- 
0.1) 
0.3 
(0.2- 
0.5) 
1.1 
(0.9- 
1.4) 
0.9  
(0.7- 
1.2) 
0.8 
  (0.6- 
1.0) 
 0.0 
(0.0- 
0.0) 
0.0 
(0.0- 
0.0) 
0.0 
(0.0- 
0.1) 
0.0 
(0.0- 
0.1) 
0.0 
(0.0- 
0.1) 
≥15 
years 
2.3 
(2.2-2.4) 
4.1 
(4.0-4.2) 
6.5 
(6.4-6.7) 
5.9 
(5.8-6.0) 
7.7 
(7.6-7.9) 
 0.0 
(0.0- 
0.0) 
0.0 
(0.0- 
0.0) 
0.0 
(0.0- 
0.0) 
0.0 
(0.0-0.0
) 
0.0 
(0.0-0.
0) 
 0.0 
(0.0- 
0.0) 
0.0 
(0.0- 
0.0) 
0.0 
(0.0- 
0.0) 
0.0 
(0.0- 
0.0) 
0.0 
(0.0- 
0.0) 
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Table 2. ORs and 95%CIs of severe illness and death among probable cases and 
laboratory-confirmed HFMD cases. Results from multivariate logistic regression 
with backward selection of demographic and geographic variables, time from onset to 
diagnosis, and virus type (p-value for exclusion≥0·10). 
 
Lab-confirmed cases 
N=267942 
Probable cases 
N=6932150 
Characteristics 
No. of 
cases 
Adjusted OR (95% 
CI) 
No. of 
cases 
Adjusted OR (95% 
CI) 
Death     
Enterovirus serotype      
    CV-A16  76817 Ref.  NA 
    Other enterovirus 56398 4.36 (2.72-6.98) 
    EV-A71 134727 34.24 (22.47-52.18) 
Age group     
  ≥5 years 22666 Ref.  638925 Ref.  
    24-59 months 131560 3.44 (2.24-5.28) 3274253 4.00 (2.12-7.55) 
    6-23 months 111238 8.75 (5.73-13.35) 2941707 8.59 (4.59-16.09) 
    <6 months 2478 20.46 (12.35-33.90) 77265 14.21 (6.59-30.62) 
Residence     
 Urban 115828 Ref. 3219524 Ref. 
 Rural 137162 1.19 (1.07-1.33) 3218311 2.45 (2.06-2.92) 
Per day increase of 
onset-to-diagnosis 
interval 
NA 1.01 (1.01-1.02) NA 1.02 (1.01-1.02) 
Sex     
 Female 96934 Ref. 4351763 Ref. 
 Male 171008 1.00 (0.90-1.11) 2580384 1.28 (1.09-1.52) 
Severe illness     
Enterovirus serotype      
    CV-A16  76817 Ref.  NA 
    Other enterovirus 56398 3.91 (3.70-4.14) 
    EV-A71 134727 11.17 (10.64-11.74)   
Age group     
  ≥5 years 22666 Ref.  638925 Ref.  
    24-59 months 131560 1.90 (1.78-2.01) 3274253 1.99 (1.89-2.10) 
    6-23 months 111238 3.64 (3.43-3.87) 2941707 3.40 (3.22-3.58) 
    <6 months 2478 5.68 (5.07-6.36) 77265 4.71 (4.33-5.12) 
CI, confidence interval; EV-A71, enterovirus 71; CA-V16, Coxsackievirus A16; Ref., 
reference; NA, not applicable; OR, odds ratio 
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Table 2. (continued) 
 
Lab-confirmed cases 
N=267942 
Probable cases 
N=6932150 
Characteristics 
No. of 
cases 
Adjusted OR (95% 
CI) 
No. of 
cases 
Adjusted OR (95% 
CI) 
Severe illness     
Residence     
    Urban 115828 Ref. 3219524 Ref. 
    Rural 137162 1.08 (1.05-1.10) 3218311 1.67 (1.64-1.71) 
Per day increase of 
onset-to-diagnosis 
interval 
NA 1.00 (1.00-1.00) NA 1.02 (1.01-1.02) 
Sex     
 Female 96934  4351763  
 Male 171008 1.10 (1.07-1.13) 2580384 1.03 (1.01-1.05) 
CI, confidence interval; EV-A71, enterovirus 71; CA-V16, Coxsackievirus A16; Ref., 
reference; NA, not applicable; OR, odds ratio 
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Panel  
Systematic review 
We searched PubMed with the keywords “Hand, Foot and Mouth Disease”, “EV71”, 
“enterovirus 71” and “coxsackie virus A” for all journal articles written in English 
between Jan 1, 1995, and June 30, 2013. In the past 15 years, EV-A71–associated 
HFMD epidemics have been increasingly reported across the Asia–Pacific region, 
chronologically including Malaysia,4 Taiwan,5 Japan,6 Singapore,7 Vietnam,8 
mainland China,9 Hong Kong SAR,10 and Cambodia.11 These reports were mostly 
descriptive, with very few exceptions that estimated epidemiologic parameters, 
assessed severity or analyzed seasonality. Even fewer had sufficient power to yield 
definitive conclusions. No previous report had addressed all three sets of interrelated 
questions. Here we report the largest study to date across a wide geographic expanse 
through the recently enhanced national surveillance network for HFMD in China.  
 
Interpretation 
We described the enhanced HFMD surveillance system, characterized host 
characteristics, periodicity of epidemics, and geographic patterns from 2008 to 2012. 
HFMD incidence was 1·2 per 1,000 person–years with 350–900 reported deaths 
annually during 2009–2012, predominantly among young children. There was strong 
age dependency, with children aged six months to two years showing the highest rates 
(Table 1). Boys under five years were 1·6 times more likely than girls of the same age 
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bracket to register disease. Overall the case–fatality, case–severity, and severe 
case–fatality risks were 0·03%, 1·1%, and 3·0% respectively. Illness severity and 
death by enterovirus serotype were inversely related to age (Table 2 and Figure 2, 
panels B–D). The median time from illness onset to diagnosis, from illness onset to 
death, and from diagnosis to death were 1·5 days (interquartile range: 0·5–2·5 days), 
3·5 days (interquartile range: 2·5–4·5 days), and 0·5 day (interquartile range: 0·5–1·5 
days) respectively. HFMD tended to occur during the warmer months of the year 
throughout the country, although peak timing and the periodicity of epidemics varied 
substantially with latitude, in particular demonstrating stronger semi-annual cycles in 
southern China compared to annual outbreaks in the north. Seasonal variation was 
associated with precipitation, sunshine, temperature, and barometric pressure. 
However, no single climatic variable was sufficient to explain the complexity of 
HFMD seasonality across China.  
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Figure Legends 
 
Figure 1. Proportions of enterovirus serotypes among laboratory-confirmed 
HFMD cases by clinical severity, 2008-2012, China. A: based on mild cases. B: 
based on severe cases who survived, C: based on fatal cases. 
 
Figure 2. Age distribution and clinical severity of probable and 
laboratory-confirmed (EV-A71, CA-V16 or other enteroviruses) HFMD cases, 
2008-2012, China. A: Age distribution of probable and lab-confirmed cases. B: Risk 
of fatality among cases by age group and viral etiology. C: Risk of severe illness 
among cases by age group and viral etiology. D: Risk of fatality among severe cases 
by age group and viral etiology. EV-A71, enterovirus 71; CA-V16, Coxsackievirus 
A16; mth, months; y, years. Severity estimates in B-D were calculated by 
extrapolating the serotype distribution among test-positive cases to untested and 
test-negative cases. That is, the number of mild cases with serotype X ( = EV-A71, 
CA-V16 or other enteroviruses) was estimated to be (no. of mild cases test-positive 
for serotype X)/(no. of test-positive mild cases) x (no. of mild cases); severe cases 
were similarly analyzed. Results were similar if only the 2010-2012 or 2012 data were 
used (Appendix Figures 4&5). 
 
Figure 3. Estimates of onset-to-diagnosis, onset-to-death, and diagnosis-to-death 
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distributions of probable and laboratory-confirmed (EV-A71, CA-V16 or other 
enteroviruses) HFMD cases, 2008-2012, China. A: Onset-to-diagnosis distribution 
by viral etiology (n=7,200,092). B: Onset-to-death distribution by viral etiology 
(n=2457). C: Diagnosis-to-death distribution by viral etiology (n=2457). Note that 
some intervals are negative because diagnosis occurred after death. 
 
Figure 4. Heatmap of HFMD surveillance data from 2008 to 2012 by Chinese 
province. The provinces were ordered by latitude from Northermost (top) to 
Southernmost (bottom). A: Time series of weekly probable and lab-confirmed HFMD 
cases, standardized by the number of annual cases. B: Seasonal distribution of HFMD 
cases, plotted as the median value of proportion of cases in each week of the year 
from 2008 to 2012. C: Number of HFMD cases by week of illness onset. The insert is 
a superposition of the number of cases without probable HFMD cases by week of 
illness onset. 
 
Figure 5. Latitudinal gradients in periodicity and peak timing of HFMD. A: 
Amplitude of the annual periodicity. B: Annual peak timing. C: Contribution of the 
semi-annual periodicity, measured by the ratio of the amplitude of the semi-annual 
periodicity to the sum of the amplitudes of annual and semi-annual periodicities 
(higher ratio indicates a stronger semi-annual periodicity). Symbol size is proportional 
to the number of cases in each province. Black solid line represent linear regression fit 
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(regression weighted by mean annual number of HFMD cases). P-values are given on 
the graphs. Colors represent different climatic zones (black: cold-temperate, blue 
mid-temperate, green warm-temperate, orange subtropical, red tropical). 
 
Figure 6. Amplitude and timing of primary HFMD epidemics in China. A: 
Amplitude of the annual cycle from yellow (low) to red (high), as indicated in the 
legend. B: Importance of the semi-annual periodicity, measured by the ratio of the 
amplitude of the semi-annual cycle to the sum of the amplitudes of annual and 
semi-annual cycles. Pale green indicates strongly annual influenza epidemics, while 
dark green indicates dominant semi-annual activity. C: Timing of primary annual 
HFMD peak, in weeks from Jan 1st. Timing is color coded from pale blue to dark 
blue. 
 
Figure 7. HFMD epidemiological regions and predictors. A: Identified 
epidemiological regions based on hierarchical clustering, using the Euclidian distance 
between weekly standardized HFMD time series. Provinces are color-coded by 
climatic region (black: cold-temperate, blue: mid-temperate, green: warm temperate, 
orange: subtropical, red: tropical). B: Map of the three epidemiological regions 
identified in panel A. C: Climate predictors of the two main clusters identified in 
panel A, based on stepwise discriminant analysis. 
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Figure 1. Proportions of enterovirus serotypes among laboratory-confirmed 
HFMD cases by clinical severity, 2008-2012, China 
A: based on mild cases. B: based on severe cases who survived, C: based on fatal 
cases. EV-A71, enterovirus 71; CV-A16, Coxsackievirus A16 
 Figure 2. Age distribution and clinical severity of probable and laboratory-confirmed HFMD cases, 
2008-2012, China  
A: Age distribution of probable and lab-confirmed cases. B: Risk of fatality among cases by age group and viral 
etiology. C: Risk of severe illness among cases by age group and viral etiology. D: Risk of fatality among 
severe cases by age group and viral etiology. EV-A71, enterovirus 71; CV-A16, Coxsackievirus A16; mth, 
months; y, years. Severity estimates in B-D were calculated by extrapolating the serotype distribution among 
test-positive cases to untested and test-negative cases. That is, the number of mild cases with serotype X ( = 
EV-A71, CV-A16 or other enteroviruses) was estimated to be (no. of mild cases test-positive for serotype 
X)/(no. of test-positive mild cases) x (no. of mild cases); severe cases were similarly analyzed. Results were 
similar if only the 2010-2012 or 2012 data were used (Appendix Figures 4&5). 
 
 
Figure 3. Estimates of onset-to-diagnosis, onset-to-death, and diagnosis-to-death distributions of probable and laboratory-confirmed 
HFMD cases, 2008-2012, China 
A: Onset-to-diagnosis distribution by viral etiology (n=7,200,092). B: Onset-to-death distribution by viral etiology (n=2457). C: 
Diagnosis-to-death distribution by viral etiology (n=2457). Note that some intervals are negative because diagnosis occurred after death. EV-A71, 
enterovirus 71; CV-A16, Coxsackievirus A16 
 
  
C 
 
B 
A 
Figure 4. HFMD surveillance data from 2008 to 2012 by Chinese province and 
by week 
The provinces were ordered by latitude from Northermost (top) to Southernmost 
(bottom). A: Time series of weekly probable and lab-confirmed HFMD cases, 
standardized by the number of annual cases. B: Seasonal distribution of HFMD 
cases, plotted as the median value of proportion of cases in each week of the year 
from 2008 to 2012. C: Number of HFMD cases by week of illness onset. The insert 
is a superposition of the number of cases without probable HFMD cases by week of 
illness onset. 
 
Figure 5. Latitudinal gradients in periodicity and peak timing of HFMD 
A: Amplitude of the annual periodicity. B: Annual peak timing. C: Contribution of the 
semi-annual periodicity, measured by the ratio of the amplitude of the semi-annual 
periodicity to the sum of the amplitudes of annual and semi-annual periodicities 
(higher ratio indicates a stronger semi-annual periodicity). Symbol size is proportional 
to the number of cases in each province. Black solid line represent linear regression fit 
(regression weighted by mean annual number of HFMD cases). P-values are given on 
the graphs. Colors represent different climatic zones (black: cold-temperate, blue 
mid-temperate, green warm-temperate, orange subtropical, red tropical).
   
Figure 6. Amplitude and timing of primary HFMD epidemics in China.  
A: Amplitude of the annual cycle from yellow (low) to red (high), as indicated in the legend. B: Importance of the semi-annual periodicity, 
measured by the ratio of the amplitude of the semi-annual cycle to the sum of the amplitudes of annual and semi-annual cycles. Pale green 
indicates strongly annual influenza epidemics, while dark green indicates dominant semi-annual activity. C: Timing of primary annual HFMD 
peak, in weeks from Jan 1st. Timing is color coded from pale blue to dark blue. 
A 
 
B          C 
 
Figure 7. HFMD epidemiological regions and predictors 
A: Identified epidemiological regions based on hierarchical clustering, using the Euclidian 
distance between weekly standardized HFMD time series. Provinces are color-coded by climatic 
region (black: cold-temperate, blue: mid-temperate, green: warm temperate, orange: subtropical, 
red: tropical). B: Map of the three epidemiological regions identified in panel A. C: Climate 
predictors of the two main clusters identified in panel A, based on stepwise discriminant analysis.  
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Appendix Text 1. Additional information regarding climate variables 
Meteorological data collected included daily temperature (min, max, mean), rainfall, 
relative humidity (min, mean), air pressure (min, max, mean), average vapor pressure, 
and hours of sunshine recorded at 756 Chinese ground weather stations from 
2008–2012.1  
In order to aggregate daily- station-specific meteorological data at the weekly and 
province level, we first averaged station–specific daily values at the weekly level 
(except for rainfall where the weekly sum was taken) and took the average across all 
stations located within a province. Preliminary analysis of HFMD surveillance data 
revealed that two HFMD peaks were typically observed in recent years in China in 
spring and autumn. Therefore, province–specific climatic variables were further 
summarized for relevant seasons, by averaging the weekly values corresponding to 
the spring (April–June) and autumn (September–November).  
 
Reference 
1. Climatic Data Center, National Meteorological Information Center, CMA. 
Available at: http://data.cma.gov.cn/index.jsp. Accessed April 04 2013. 
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Appendix Text 2. Additional information regarding the estimation of seasonal 
parameters 
1. Regression model 
We used to following linear regression model to estimate the peak timing and 
amplitude of the annual and semi-annual periodicities of influenza activity in each 
province, as described in1,2: 
hfmdi(t)=a+ bi *cos(2Pi*t/52.17) +  ci *sin(2Pi*t/52.17) +  di*cos(4Pi*t/52.17) +  
ei *sin(4Pi*t/52.17) + ε(t) 
where hfmdi(t) are the weekly standardized counts of HFMD cases (or EV-A71, or 
CV-A16, or other enterovirus) isolates in province i, where standardization is 
obtained by dividing weekly values by the annual number of HFMD cases, t is a 
running index for week, and a,b, c, d and e are the intercept and seasonal terms to be 
estimated from the data. 
Specifically,  
the amplitude of the annual periodicity is estimated as AnnAmpi=sqrt(bi 2+ ci 2),  
the annual peak timing is estimated as AnnPeakTimingi=-atan(ci / bi),  
the amplitude of the semi-annual periodicity is estimated as 
SemiAnnAmpi=sqrt(c2+d2) 
To evaluate the relative importance of annual and semi-annual HFMD periodicities by 
province, we calculated the ratio between the amplitude of the semi-annual periodicity 
and the sum of the amplitudes of annual and semi-annual periodicities. A ratio close to 
1 is indicative of dominant semi-annual periodicity while a ratio close to 0 indicates 
3 
 
dominant annual periodicity.  
The ratio is estimated as Ratioi= SemiAnnAmpi / (SemiAnnAmpi + AnnAmpi) 
 
To control for different levels of HFMD activity across provinces, we compare the 
relative amplitudes of annual and semi-annual periodicity, obtained by dividing 
AnnAmpi and SemiAnnAmpi by the mean of the hfmdi(t) time series. 
 
2. Sensitivity analyses 
We considered alternative seasonal regression models using a Poisson distribution 
and a log link (given that we were using modified disease counts), with or without an 
offset for the number of specimens tested. Given that all three approaches gave 
sensibly similar results, we elected to use the linear model in the main analysis for 
the sake of simplicity. 
 
Reference 
1. Naumova EN, Jagai JS, Matyas B, DeMaria A, Jr., MacNeill IB, Griffiths JK. 
Seasonality in six enterically transmitted diseases and ambient temperature. 
Epidemiol Infect. 2007; 135: 281-92. 
2. Yu H, Alonso WJ, Feng L, Tan Y, Shu Y, Yang W, Viboud C. Characterization of 
regional influenza seasonality patterns in China and implications for vaccination 
strategies: spatio-temporal modelling of surveillance data. PLoS Med. 2013: 
Nov 19. In Press 
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Appendix Table 1. Association between HFMD, EV71, CA16 and other enteroviruses seasonal patterns and geographic, population, 
economic, transport and climatic factors 
Analyzed 
factors 
Overall cases EV71 confirmed cases 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value
, R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Latitude <0.001, 
0.12 
     0.001,  
0.05 
  0.004,  
0.20 
Longitude 0.032, 
0.03 
  0.016,  
0.09 
0.012, 
 0.06 
0.002, 
0.15 
    
Population size <0.001, 
0.19 
    0.048, 
0.05 
<0.001,  
0.06 
   
Area 0.021, 
0.04 
 <0.001, 
0.09 
   0.004,  
0.03 
0.013, 
0.11 
  
Density 0.032, 
0.03 
         
Passengers           
by railways   0.006, 
0.03 
     0.005,  
0.21 
0.025,  
0.11 
by highways  0.018,  
0.04 
0.006, 
0.03 
   <0.001, 
0.07 
 0.005,  
0.21 
0.025,  
0.11 
by waterways   0.006, 
0.03 
     0.005,  
0.21 
0.025,  
0.11 
by airways   0.008, 
0.03 
   0.038, 
0.01 
   
Analyses were based on stepwise multivariate regression
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Appendix Table 1. (continued) 
Analyzed 
factors 
Overall cases EV71 confirmed cases 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Total 
passengers 
 0.019,  
0.04 
0.006, 
0.03 
 0.037,  
0.04 
 <0.001,  
0.08 
 0.005,  
0.21 
0.025,  
0.11 
GRP per capita 0.029, 
0.03 
 0.001, 
0.06 
     0.038,  
0.10 
0.027,  
0.11 
Rainfall1   0.003, 
0.05 
    0.031, 
0.08 
  
Sunshine1 <0.001, 
0.12 
 <0.001, 
0.08 
    0.018, 
0.10 
  
Air pressure1           
max 0.019, 
0.04 
    0.016, 
0.08 
    
mean   0.023, 
0.02 
       
min   0.009, 
0.03 
  0.014, 
0.08 
    
Relative 
humidity1 
          
mean   0.04, 
0.02 
  <0.001, 
0.23 
    
min      <0.001, 
0.26 
    
1Spring weather parameters
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Appendix Table 1. (continued) 
Analyzed 
factors 
Overall cases EV71 confirmed cases 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Temperature1           
max 0.036, 
0.03 
    0.019, 
0.07 
    
mean   0.007, 
0.03 
  0.049, 
0.05 
    
min   0.007, 
0.03 
       
Vapor 
pressure1 
0.022, 
0.04 
         
Rainfall2  0.003, 
0.08 
        
Sunshine2  0.006, 
0.06 
 0.017, 
0.09 
  0.045, 
0.01 
 0.009, 
0.17 
 
Air pressure2           
max  0.024, 
0.04 
 0.009, 
0.11 
  <0.001, 
0.21 
   
mean  0.032, 
0.03 
    <0.001, 
0.08 
   
min    0.032, 
0.07 
  <0.001, 
0.11 
   
1Spring weather parameters  
2Autumn weather parameters 
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Appendix Table 1. (continued) 
Analyzed 
factors 
Overall cases EV71 confirmed cases 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Temperature2           
max    0.027, 
0.07 
  <0.001, 
0.06 
   
mean    0.010, 
0.11 
0.043, 
0.04 
 <0.001, 
0.06 
   
min    0.012, 
0.10 
0.033, 
0.04 
 <0.001, 
0.06 
 0.044, 
0.10 
0.048, 
0.08 
Relative 
humidity2 
          
mean           
min       <0.001, 
0.07 
   
Vapor 
pressure2 
 0.044, 
0.03 
  0.030, 
0.05 
     
Total explained 
variance3 0.832 0.817 0.910 0.623 0.755 0.671 0.915 0.646 0.397 0.457 
2Autumn weather parameters 
3Explained variance by multivariate best fit models selected by stepwise regression 
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Appendix Table 1. (continued) 
Analyzed 
factors 
CA16 confirmed cases Other enterovirus confirmed cases 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, 
R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Latitude <0.001, 
0.16 
<0.001, 
0.23 
0.011, 
0.07 
       
Longitude 0.003, 
0.10 
  <0.001, 
0.41 
0.009, 
0.16 
    0.002, 
0.21 
Population size       0.007, 
0.05 
   
Area   0.028, 
0.05 
0.007, 
0.09 
 0.040, 
0.07 
 0.034, 
0.06 
  
Density   0.011, 
0.07 
     0.027, 
0.06 
 
Passengers           
by railways  0.003, 
0.13 
      0.003, 
0.12 
 
by highways  0.003, 
0.13 
      0.003, 
0.12 
 
by waterways 0.004, 
0.09 
0.003, 
0.13 
 0.002, 
0.14 
 0.048, 
0.06 
0.021, 
0.04 
 0.003, 
0.12 
 
by airways  0.042, 
0.05 
        
Analyses were based on stepwise multivariate regression
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Appendix Table 1. (continued) 
Analyzed 
factors 
CA16 confirmed cases Other enterovirus confirmed cases 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Total 
passengers 
0.018, 
0.06 
0.003, 
0.13 
      0.003, 
0.12 
 
GRP per capita   0.049, 
0.03 
0.008, 
0.09 
0.012, 
0.15 
 0.005, 
0.06 
0.006, 
0.12 
0.012, 
0.08 
 
Rainfall1   <0.001, 
0.23 
    0.005, 
0.12 
  
Sunshine1   <0.001, 
0.23 
    0.006, 
0.12 
  
Air pressure1           
max 0.034, 
0.05 
    0.010, 
0.12 
    
mean 0.032, 
0.05 
 0.020, 
0.05 
  0.008, 
0.13 
    
min   0.008, 
0.08 
       
Relative 
humidity1 
          
mean 0.004, 
1.10 
         
min 0.001, 
0.13 
    0.003, 
0.17 
    
1Spring weather parameters
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Appendix Table 1. (continued) 
Analyzed 
factors 
CA16 confirmed cases Other enterovirus confirmed cases 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Temperature1           
max   0.020, 
0.05 
  0.014, 
0.10 
    
mean   0.010, 
0.07 
    0.025, 
0.07 
  
min   0.008, 
0.08 
    0.025, 
0.07 
  
Vapor 
pressure1 
     0.005, 
0.14 
    
Rainfall2    0.005, 
0.10 
  <0.001, 
0.11 
 0.003, 
0.12 
0.032, 
0.09 
Sunshine2  0.004, 
0.12 
    0.005, 
0.06 
 0.034, 
0.05 
 
Air pressure2           
max    0.033, 
0.05 
  0.22, 
0.04 
   
mean       0.018, 
0.04 
 <0.001, 
0.27 
0.007, 
0.15 
min    0.046, 
0.05 
    <0.001, 
0.17 
0.009, 
0.14 
1Spring weather parameters  
2Autumn weather parameters 
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Appendix Table 1. (continued) 
Analyzed 
factors 
CA16 confirmed cases Other enterovirus confirmed cases 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Timing (phase) Amplitude Importance 
semi-annual 
periodicity 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Annual 
cycle 
(p-value, 
R2) 
Semi-annual 
cycle 
(p-value, R2) 
Temperature2           
max    0.002, 
0.13 
     0.020, 
0.11 
mean    0.002, 
0.13 
     0.011, 
0.13 
min    0.007, 
0.09 
    0.007, 
0.09 
 
Relative 
humidity2 
          
mean    0.015, 
0.07 
    0.014, 
0.07 
 
min    0.017, 
0.07 
      
Vapor 
pressure2 
 0.001, 
0.17 
       0.002, 
0.21 
Total explained 
variance3 0.739 0.704 0.799 0.701 0.401 0.591 0.823 0.708 0.719 0.507 
2Autumn weather parameters 
3Explained variance by multivariate best fit models selected by stepwise regression  
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Appendix Figure 1. Flowchart of data and sample collection for HFMD cases, 2008-12, China 
The enhanced surveillance system requires that each probable or confirmed case be reported on-line to the national CDC within 24 hours of 
HFMD cases 
Mild cases Severe cases 
Defined as HFMD case with 
any following complication: 
- aseptic meningitis 
- encephalitis 
- encephalomyelitis 
- AFP 
- ANS dysregulation 
pulmonary oedema 
- pulmonary haemorrhage 
cardiorespiratory failure 
Samples 
collected for 
laboratory 
test 
 
5 cases each 
week in each 
province 
Positive test 
for enterovirus 
Lab-confirmed cases 
Samples collected 
from each case Without 
samples 
collection 
Negative test 
for enterovirus 
Probable cases 
Laboratory test  
for enterovirus 
Negative test 
for enterovirus 
Filling a form, collect epidemiological, 
clinical and laboratory analysis data 
Reporting to HFMD 
surveillance system 
Visiting hospital 
May 2008 to 
June 2009 
5 cases each 
month in 
each county 
 
Since June 
2009 
Positive test 
for enterovirus 
Lab-confirmed cases 
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diagnosis. Data are updated as appropriate throughout the course of illness, and particularly at the conclusion of each episode. AFP=acute flaccid 
paralysis. ANS=autonomic nervous system. 
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Appendix Figure 2. Map of the Chinese mainland provinces  
31 Chinese mainland provinces were included in this analysis. The different colors 
represent the different climatic or geographic regions. (A) Geographic regions in 
Mainland China. Blue: mid-temperate region; green: warm-temperate region; black: 
cold region; red: sub-tropic region; turquoise: tropic region. (B) Geographic regions in 
Mainland China. Northeast: Liaoning, Jilin, Heilongjiang; North: Beijing, Tianjing, 
Hebei, Shanxi, Inner Mongolia; Northwest: Shaanxi, Gansu, Qinghai, Ningxia, 
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Xinjiang; East: Shanghai, Jiangsu, Zhejiang, Anhui, Fujian, Jiangxi, Shandong; 
Central: Henan, Hubei, Hunan; Southwest: Chongqing, Sichuan, Guizhou, Yunnan, 
Tibet; South: Guangdong, Guangxi, Hainan. 
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Appendix Figure 3. Proportions of enterovirus serotypes among laboratory-confirmed HFMD cases by week of illness onset and by 
geographic region, 2008-12, China  
EV71=enterovirus 71. CV-A16=Coxsackievirus A16. 
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Figure 4. Age distribution and clinical severity of probable and 
laboratory-confirmed HFMD cases, 2010-12, China 
(A) Age distribution of probable and lab-confirmed cases. (B) Risk of fatality among 
cases by age group and viral etiology. (C) Risk of severe illness among cases by age 
group and viral etiology. (D) Risk of fatality among severe cases by age group and 
viral etiology. EV71=enterovirus 71. CV-A16=Coxsackievirus A16. mth=months. 
y=years. 
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Figure 5. Age distribution and clinical severity of probable and 
laboratory-confirmed HFMD cases, 2012, China 
(A) Age distribution of probable and lab-confirmed cases. (B) Risk of fatality among 
cases by age group and viral etiology. (C) Risk of severe illness among cases by age 
group and viral etiology. (D) Risk of fatality among severe cases by age group and 
viral etiology. EV71=enterovirus 71. CV-A16=Coxsackievirus A16. mth=months. 
y=years. 
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Appendix Figure 6. Latitudinal and longitudinal gradients in seasonality of EV71, 
CV-A16 and other enterovirus 
Figure shows that all enteroviruses exhibited latitudinal gradients in the amplitude of 
annual and semiannual epidemics. Annual peak timing of CA-V16 activity occurred 
earlier than for other enteroviruses (p=0·0148). Southern provinces experienced 
earlier spring and fall epidemics of EV71 and other enterovirus than Northern 
provinces (difference between the annual peak timing of epidemics in Northern and 
that in Southern in EV71: p=0·031, in other enterovirus: p=0·21; difference between 
the semiannual peak timing of epidemics in Northern and that in Southern in EV71: 
p= 0·0008, in other enterovirus: p= 0·0008). The timing of fall EV71 epidemics was 
also associated with longitude, with later occurrence in coastal provinces. 
EV71=enterovirus 71. CV-A16=Coxsackievirus A16. 
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Appendix Figure 7. Periodicity of EV71, CV-A16 and other enterovirus epidemics in China 
Importance of the semiannual periodicity, measured by the ratio of the amplitude of the semiannual cycle to the sum of the amplitudes of annual 
and semiannual cycles. EV71=enterovirus 71. CV-A16=Coxsackievirus A16. 
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Appendix Figure 8. Importance of semiannual seasonality of EV71, CV-A16 and 
other enterovirus 
Importance of the semiannual periodicity, measured by the ratio of the amplitude of 
the semiannual cycle to the sum of the amplitudes of annual and semiannual cycles. 
EV71=enterovirus 71. CV-A16=Coxsackievirus A16. 
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Appendix Figure 9. EV71 epidemiological regions and predictors 
(A) Identified epidemiological regions based on hierarchical clustering, using the 
Euclidian distance between weekly standardized EV71 time series. Provinces are 
color-coded by climatic region (see legends of appendix figure 1). (B) Map of the 
three epidemiological regions identified in panel A. (C) Predictors of the two main 
clusters identified in panel A, based on stepwise discriminant analysis.  
14 
 
A 
 
B            C              D 
         
15 
 
Appendix Figure 10. CV-A16 epidemiological regions and predictors 
(A) Identified epidemiological regions based on hierarchical clustering, using the Euclidian distance between weekly standardized CV-A16 time 
series. Provinces are color-coded by climatic region (see legends of appendix figure 1). (B) Map of the three epidemiological regions identified 
in panel A. (C) Climate predictors of the two main clusters identified in panel A, based on stepwise discriminant analysis. (D) Climate 
predictors of the two sub-clusters identified in panel A, based on stepwise discriminant analysis. 
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Appendix Figure 11. Other enteroviruses epidemiological regions and 
predictors 
(A) Identified epidemiological regions based on hierarchical clustering, using the 
Euclidian distance between weekly standardized other enterovirus time series. 
Provinces are color-coded by climatic region (black: cold-temperate, blue: 
mid-temperate, green: warm temperate, orange: subtropical, red: tropical). (B) Map 
of the three epidemiological regions identified in panel A. (C) Climate predictors of 
the two main clusters identified in panel A, based on stepwise discriminant analysis.  
 
